Skip to main content

Table 1 Baseline characteristics. N = 662

From: Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens

Variable

Result

Median age in years, IQR

50 (41,57)

Sex, % male

48.79

Weight, mean (SD) kg

71.8 (13.1)

Obesity (% obese)

16.62

Hypertension, %

6.95

Diabetes, %

28.25

Hepatitis B virus coinfection

1.36

Cirrhosis, overall %

49.40

 Cirrhosis compensated, %

89.27

 Cirrhosis decompensated, %

10.73

HCV RNA, median log10 IU/mL (IQR)

5.90 (5.20,6.45)

HCV genotype

 HCV genotype 3

90.79

 HCV genotype non-3

9.21

Sustained virologic response, %

91.90

Incident HCC, %

6.34

Median time to HCC, weeks (IQR)

28 (21,39)

Treatment regimen, %

 SOF/RBV/PEG-IFN

25.23

 SOF/RBV

62.24

 SOF/DCV/RBV

10.57

 SOF/DCV

1.96

  1. IQR inter-quartile range, HCC hepatocellular carcinoma, SOF sofosbuvir, RBV ribavirin, PEG-IFN pegylated interferon, DCV daclatasvir;